Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GRK2 | P25098 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25978243 | 0.84 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL21793207 | 0.74 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL25532220 | 0.71 | MEN1 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8215935 | 0.69 | HDAC3 (0.41) | — | |
| SCHEMBL9369077 | 0.69 | MEN1 (0.38) | MEN1LMNAKMT2ABLM | |
| SCHEMBL20203132 | 0.67 | ALDH1A1 (0.48) | ALDH1A1POLBGRK2L3MBTL1MEN1 | |
| SCHEMBL13669849 | 0.67 | ALDH1A1 (0.42) | ALDH1A1POLBLMNABLM | |
| SCHEMBL13126746 | 0.66 | ALDH1A1 (0.56) | ALDH1A1POLBGRK2L3MBTL1MEN1 | |
| SCHEMBL11342239 | 0.66 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ARECQLBLM | |
| SCHEMBL25597226 | 0.66 | ALDH1A1 (0.47) | ALDH1A1POLBGRK2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | ALDH1A1 2955/4885POLB 4807/4885GRK2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.